Angiex Inc

Nuclear-Delivered Antibody-Drug Conjugates that deliver chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells, offering exceptional efficacy and therapeutic margin for solid cancers.

Completed $31M financing for Phase 1 clinical development, dosed first patient in Phase 1 clinical trial of lead asset AGX101, and received FDA clearance of IND application for AGX101.